Albert Knouse, MD
Family Medicine · Newport, PANPI 1871553842
Payments from drug & device makers
Across 442 payments — averaging $1969.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$530K
- Eli Lilly$323K
- Sanofi US Services Inc.$12K
- Novo Nordisk$787
- GSK$676
- Pfizer$507
- plus $4K from 31 others
Across 3 payments — averaging $30,699 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$92K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $530,016 |
| Eli Lilly | 10 | $322,928 |
| Sanofi US Services Inc. | 4 | $11,875 |
| Novo Nordisk | 61 | $787 |
| GSK | 65 | $676 |
| Pfizer | 52 | $507 |
| Boehringer Ingelheim | 34 | $503 |
| AstraZeneca(2 entities) | 26 | $448 |
| AbbVie(2 entities) | 20 | $398 |
| Amgen | 21 | $388 |
| Lilly USA, LLC | 27 | $301 |
| Merck | 17 | $275 |
| Johnson & Johnson(2 entities) | 13 | $222 |
| E.r. Squibb & Sons, L.L.C. | 9 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $137 |
| Sanofi Pasteur Inc. | 5 | $129 |
| Amarin Pharma, Inc. | 6 | $106 |
| Sanofi-aventis U.S. LLC | 7 | $101 |
| Biohaven Pharmaceuticals, Inc. | 5 | $86 |
| Astellas Pharma US Inc | 4 | $80 |
| Abbott | 3 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $48 |
| Grifols USA, LLC | 3 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Genentech USA, Inc. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Organogenesis Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Corium, LLC | 1 | $14 |
| Cequr Corporation | 1 | $14 |
How this compares
$870,609 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Newport
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.